KERYX BIOPHARMACEUTICALS INC
DelistedCIK 1114220fmd_1SVGPVQ7GV41JSWE2P82ZMHP5QManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2018, 35 periods
| Line item | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 25 | 0 | 5 | 0 | 7 | 11 | 14 | 32 | 61 |
| Cost of revenue | – | – | – | – | – | 0 | 5 | 38 | 22 |
| Realized investment gains (losses) | – | (0) | 0 | 0 | – | – | – | – | – |
| Gross profit | – | – | – | – | – | 11 | 9 | (6) | 39 |
| Research and development | 9 | 15 | 27 | 20 | 35 | 52 | 37 | 30 | 38 |
| Selling, general and administrative | – | – | – | 7 | 19 | 70 | 81 | 85 | 100 |
| Total operating expenses | 15 | 21 | 34 | 27 | 54 | 122 | 125 | 155 | 162 |
| Operating income | 10 | (21) | (29) | (27) | (47) | (111) | (111) | (123) | (102) |
| Interest expense | – | – | – | – | – | 0 | 11 | 34 | 63 |
| Interest and investment income | – | – | – | – | 0 | 0 | 0 | 1 | 1 |
| Other non-operating income (expense) | 1 | 1 | 0 | 2 | 0 | 0 | (12) | (38) | (62) |
| Income before taxes | 10 | (20) | (28) | (25) | (47) | (111) | (123) | (161) | (164) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 1 | 0 | 0 | (0) |
| Net income from continuing operations | 10 | (20) | (28) | (25) | (47) | (112) | (123) | (161) | (163) |
| Net income | 10 | (20) | (28) | (23) | (47) | (112) | (123) | (161) | (163) |